A 2-Month Safety Follow-up Trial of Subjects From MannKind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030.

Trial Profile

A 2-Month Safety Follow-up Trial of Subjects From MannKind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2014

At a glance

  • Drugs Insulin (Primary) ; Antihyperglycaemics
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 24 Apr 2010 Results were presented at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster 267), according to a MannKind Corporation media release.
    • 23 May 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 22 May 2009 Actual patient number (672) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top